Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03048825 · ClinicalTrials.gov registry record · Phase 3
Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry
A Phase 3 study, sponsored by Population Health Research Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,264
- Enrollment target
NCT03048825 is a Phase 3 study that has completed, run by Population Health Research Institute. The registered enrollment target is 7,264 participants.
The verdict
NCT03048825, a Phase 3 study, has completed, sponsored by Population Health Research Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,264 participants
- Enrollment target
Study Summary
The CLEAR SYNERGY trial will study the long term effects of treatments following PCI to treat myocardial infarction. These treatments address both the culprit artery (PCI with SYNERGY stent) as well as the non-culprit arteries (randomization to routine colchicine and spironolactone).
Interventions
- DRUG Spironolactone
- DRUG Colchicine
- DRUG Colchicine-Placebo
- DEVICE SYNERGY Bioabsorbable Polymer Drug-Eluting Stent
- DRUG Spironolactone-Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,264 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2024-08-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03048825
The ClinicalTrials.gov registry entry for NCT03048825 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 7,264 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Population Health Research Institute, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Spironolactone is the first listed.
NCT03048825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03048825 about?
NCT03048825 is a clinical study titled "Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry". The CLEAR SYNERGY trial will study the long term effects of treatments following PCI to treat myocardial infarction. These treatments address both the culprit artery (PCI with SYNERGY stent) as well as the non-culprit arteries (randomization to routine colchicine and spironolactone).
What is the current status of trial NCT03048825?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,264 participants. The study started on 2018-02-01. Estimated completion is 2024-08-09.
What interventions are being tested in trial NCT03048825?
The interventions under investigation include: Spironolactone (DRUG), Colchicine (DRUG), Colchicine-Placebo (DRUG), SYNERGY Bioabsorbable Polymer Drug-Eluting Stent (DEVICE), Spironolactone-Placebo (DRUG).
Who is sponsoring clinical trial NCT03048825?
This trial is sponsored by Population Health Research Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.